The Biotech IPO That Came Back From the Dead

The lead candidate, OD-001, is an oral RIPK2 inhibitor (RIPK2 being one of those immune signaling nodes) currently in Phase 2 trials for ulcerative colitis. There's also a combination study running with Takeda's Entyvio. Behind that sits an SLC15A4 program targeting lupus, with about $50 million of IPO proceeds earmarked to push it into Phase 1/2a trials.

The People Behind the Curtain

Odyssey's founder and CEO is Gary D. Glick, a serial biotech entrepreneur whose track record reads like someone playing the game on easy mode. He previously founded IFM Therapeutics (whose assets sold for over $4 billion), Lycera Corp. (partnered with Merck), and co-founded Scorpion Therapeutics (which raised $270 million). The guy knows how to build companies that bigger fish want to eat.

The board chair is Jeffrey M. Leiden, the former CEO of Vertex Pharmaceuticals. And the bench includes veterans from Novartis, Pfizer, and BMS. OrbiMed Advisors and SR One Capital Management led the early venture rounds, which totaled over $700 million before the IPO even happened.

When you stack that kind of pedigree together, it explains why investors came back with bigger checks the second time around.

A Barometer for the Biotech IPO Window

Odyssey's success isn't happening in isolation. The 2026 biotech IPO market has been quietly roaring. Aktis Oncology raised $318 million in January (upsized from $181 million). Eikon Therapeutics grabbed $381 million shortly after. Seaport Therapeutics pulled in $255 million just last week. Analysts now project 30 to 35 biotech IPOs for the full year.

What's driving the thaw? A massive M&A wave is recycling capital back to investors. Twelve biopharma deals worth $1 billion or more were announced in just the first quarter of 2026. When Merck spends $6.7 billion on Terns and Eli Lilly drops $6.3 billion on Centessa, the funds that owned those companies suddenly have cash to deploy into fresh stories.

Michael Rachlin of FTI Consulting described it as a "more discerning IPO marketplace" that favors "drug innovators with proven, later-stage assets." Odyssey fits that profile: clinical data in hand, a clear path forward, and a management team that's done this before.

The Risks Nobody's Talking About

Let's not pretend this is a sure thing. Odyssey reported just $3 million in revenue over the twelve months ending December 2025. The company is burning cash to fund clinical trials that may or may not work. Phase 2 is still early; plenty of promising drugs crater in Phase 3 when tested in larger, more diverse patient populations.

The autoimmune space is also getting crowded. Every major pharma company wants a piece of it, which means Odyssey's drugs will eventually compete against deep-pocketed rivals even if they succeed clinically.

And there's the elephant in the room: scaffolding inhibition is a novel mechanism. Novel is exciting for investors. Novel is terrifying for regulators. The FDA will want robust safety data before blessing a fundamentally new approach to modulating immune signaling.

The Bottom Line

Odyssey's IPO is the biotech equivalent of showing up to your high school reunion in a better car. The company that couldn't get a deal done in 2025 just pulled off one of the largest biotech offerings of the year. It signals that investors are genuinely hungry for clinical-stage autoimmune stories, especially when the team has a track record.

Whether the science delivers is a question for 2027 and beyond. But today? Today belongs to the comeback kid.

Italy's Biggest Bet on American Biotech Just Landed

A 107-year-old Italian pharma just dropped $4.1 billion on a Florida rare disease company. Angelini's acquisition of Catalyst Pharmaceuticals is its biggest bet ever, and it comes with a patent settlement that locks out generics until 2035.